Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

KODIAK SCIENCES INC.

(KOD)
  Report
Real-time Estimate Cboe BZX  -  02:03 2022-11-29 pm EST
7.200 USD   +0.70%
11/16Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
PR
11/14Morgan Stanley Trims Price Target on Kodiak Sciences to $9 From $12, Maintains Equalweight Rating
MT
11/10Goldman Sachs Adjusts Price Target on Kodiak Sciences to $8 From $9, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Kodiak Sciences : 22nd EURETINA Presentation

09/02/2022 | 11:09am EST

KSI-301Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion:

Primary 24-Week Efficacy and Safety Outcomes

of the BEACON Phase 3 Pivotal Study

Arshad M. Khanani, M.D., M.A., FASRS

Director of Clinical Research, Sierra Eye Associates, Reno, NV USA

on behalf of the BEACON Study Group

2 September 2022

Disclosures

  • Presenter's Financial Disclosures:
    • Consultant: Abbvie, Adverum, AGTC, Aldebaran Therapeutics, Alimera, Apellis, Arrowhead, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Cholgene, 4DMT, Eyepoint, Frontera Therapeutics, Gemini, Genentech, Inc., Graybug, Gyroscope, Iveric Bio, Janssen, Kartos Therapeutics, Kato Pharma, Kodiak, Kriya Therapeutics, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Nanoscope, Novartis, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Stealth, Thea, Unity Bio, Vanotech, Vial
    • Research Support: Adverum, Alkahest, Annexon, Apellis, Asclepix, 4DMT, Gemini, Genentech, Inc., Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio
    • Speaker: Abbvie, Apellis, Bausch and Lomb, Genentech, Inc., Novartis
    • Equity: Aviceda, Recens Medical, Retrotope, RevOpsis, PolyPhotonix
  • This presentation will discuss IRB/IEC approved research of an investigational medicine.

2

RVO real-worldanti-VEGF treatment outcomes fall short of clinical trial outcomes - more durable treatments are needed

# Eyes

Mean VA Change (Letters)

BRVO

3,000

2,637

2,500

2,049

2,000

1,699

1,500

1,082

1,000

635

354

413

500

0

1

2

3

4

5

6

7

# Injections in first 6 months

20

15

13.1

10

8.0

5

0

1

2

3

4

5

6

7

# Injections in first 6 months

# Eyes

Mean VA Change (Letters)

2,500

2,000

1,500

1,000

500

0

20

15

10

5

0

CRVO

2,043

1,567

1,311

440

837

203

327

1 2 3 4 5 6 7

  • Injections in first 6 months
    14.4

5.3

1 2 3 4 5 6 7

# Injections in first 6 months

Monthly dosing is difficult to achieve in clinical practice, where 72% of patients

received less than monthly dosing.

With currently available anti-VEGFs, treatment less often than monthly compromises vision outcomes in RVO

A less frequent therapy that

achieves comparable outcomes would be an important advance

Adapted from Ciulla T, et al. Br J Ophthalmol 2021;105:1696-1704.doi:10.1136/bjophthalmol-2020-317337. Represents 8,876 BRVO eyes, 6,737 CRVO eyes from Vestrum database. Mean 4.5 and 4.6 anti-VEGF injections over first 6

3

months (aflibercept, ranibizumab, or bevacizumab) in BRVO and CRVO, respectively. VA, Visual acuity. RVO, retinal vein occlusion. BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion.

KSI-301 (tarcocimab tedromer): Antibody Biopolymer Conjugates (ABCs)

A novel class of biologics engineered for increased durability and efficacy

+=

ANTIBODY

BIOPOLYMER

CONJUGATE

lgG1 Anti-VEGF Antibody

Branched, Optically Clear,

Immunologically inert

High Molecular Weight

Phosphorylcholine Polymer

KSI-301 (tarcocimab tedromer) is an anti-VEGF ABC that blocks all VEGF-A isoforms

4

BEACON: Phase 3 non-inferiority study of tarcocimab tedromer every 2 months after only two loading doses vs aflibercept every 1 month in treatment-naïve RVO patients

Matched

Maintenance phase

PE

phase

Week

0

4

8

12

16

20

24

Tarcocimab tedromer 5 mg Q8W

(N~275)

Aflibercept 2 mg Q4W

(N~275)

Tarcocimab injection

Primary Endpoint:

Aflibercept injection

Sham injection

Mean change in BCVA at Week 24

Hierarchical testing for control of type 1 error: 1. Test non-inferiority in BRVO patients

2. Test non-inferiority in all RVO patients (BRVO+CRVO)

[only performed if test #1 successful]

Months 6-12:Masked H2H individualized dosing

Months 12-18:

Open label with individualized dosing

Clinicaltrials.gov, study identifier: NCT04592419

5

RVO: retinal vein occlusion; PE: primary endpoint; H2H: head-to-head; BCVA: best-corrected visual acuity

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Kodiak Sciences Inc. published this content on 02 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2022 15:08:03 UTC.


ę Publicnow 2022
All news about KODIAK SCIENCES INC.
11/16Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
PR
11/14Morgan Stanley Trims Price Target on Kodiak Sciences to $9 From $12, Maintains Equalwei..
MT
11/10Goldman Sachs Adjusts Price Target on Kodiak Sciences to $8 From $9, Maintains Neutral ..
MT
11/09KODIAK SCIENCES INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
11/09Earnings Flash (KOD) KODIAK SCIENCES Reports Q3 Loss $-1.47
MT
11/09Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business High..
PR
11/09Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
09/30Kodiak Sciences : 2022 American Academy of Ophthalmology Presentation
PU
09/14Transcript : Kodiak Sciences Inc. Presents at Morgan Stanley 20th Annual Glob..
CI
09/07Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
PR
More news
Analyst Recommendations on KODIAK SCIENCES INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -345 M - -
Net cash 2022 436 M - -
P/E ratio 2022 -1,08x
Yield 2022 -
Capitalization 372 M 372 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 105
Free-Float 94,3%
Chart KODIAK SCIENCES INC.
Duration : Period :
Kodiak Sciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KODIAK SCIENCES INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 7,15 $
Average target price 12,70 $
Spread / Average Target 77,6%
EPS Revisions
Managers and Directors
Victor Perlroth Chairman, President & Chief Executive Officer
John A. Borgeson Chief Financial Officer & Senior Vice President
Jason S. Ehrlich Chief Medical & Development Officer
Pablo Velazquez-Martin VP-Clinical Research & Translational Medicine
Michael S. Louie Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
KODIAK SCIENCES INC.-91.57%372
VERTEX PHARMACEUTICALS43.58%80 935
REGENERON PHARMACEUTICALS, INC.16.58%79 191
BIONTECH SE-37.36%39 245
WUXI APPTEC CO., LTD.-35.85%30 708
GENMAB A/S22.93%29 471